Latest news
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeatMarketBeat · Sat, 08 Aug 2026 05:48:57 GMTCompass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeatMarketBeat · Sat, 08 Aug 2026 04:52:38 GMTCompass Therapeutics Inc. (CMPX) Stock News Today - TradingKeyTradingKey · Fri, 07 Aug 2026 21:09:18 GMTCMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - StocktwitsStocktwits · Fri, 07 Aug 2026 02:58:05 GMTCompass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:13 GMTCompass Therapeutics, Inc. Q2 2026 Financial Results: Balance Sheet, Losses & Key Highlights from CMPX 10-Q Filing - MinichartMinichart · Thu, 06 Aug 2026 23:02:00 GMTCompass Therapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Operating Expenses - Kalkine MediaKalkine Media · Thu, 06 Aug 2026 17:40:23 GMTCompass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 12:11:09 GMT